This Article Full Text Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ravn, H. B. Articles by Husted, S. E.ær Search for Related Content PubMed PubMed Citation Articles by Ravn, H. B. Articles by Husted, S. E.ær Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information Heart Attack Hazardous Substances DB MAGNESIUM COMPOUNDS MAGNESIUM, ELEMENTAL

(Arteriosclerosis, Thrombosis, and Vascular Biology. 1997;17:3620-3625.)
© 1997 American Heart Association, Inc.

Articles

Early Administration of Intravenous Magnesium Inhibits Arterial Thrombus Formation

Hanne Berg Ravn; Steen Dalby Kristensen; Vibeke Elisabeth Hjortdal; Kristian Thygesen; ; Steen Elkjær Husted

From the Department of Medicine and Cardiology, Aarhus Amtssygehus, Aarhus University Hospital (H.B.R., K.T., S.E.H.); the Department of Cardiology, Skejby Sygehus, Aarhus University Hospital (S.D.K.); and the Institute of Experimental Clinical Research, Aarhus University (H.B.R., V.E.H.), Aarhus Denmark.

Correspondence to Hanne B. Ravn, MD, PhD, Institute of Experimental Clinical Research, Skejby Sygehus, Aarhus University Hospital, DK-8200 Aarhus N, Denmark. E-mail hbr{at}iekf.aau.dk

Abstract An antiplatelet effect of magnesium has been demonstrated in vitro and ex vivo, and this effect may be advantageous in patients with acute myocardial infarction to inhibit reocclusion after coronary angioplasty or thrombolysis. We investigated the antithrombotic in vivo effect of intravenous magnesium in a placebo-controlled, blinded study in 46 male Wistar rats. Thrombus formation was induced by standardized arteriotomy of the femoral artery and partial inversion of the vessel wall to produce a thrombogenic area. The vessel was transilluminated and visualized dynamically by in vivo microscopy. Thrombus area was measured every minute for 30 minutes after removal of the vessel clamp by image analysis techniques, and the number of visible emboli was registered. Animals were randomized into three groups: groups 1 and 2 received saline (control group, n=15) or MgSO₄ (Mg-early group, n=15), respectively, during the entire infusion period. In group 3 intravenous saline was given during preparation of the arteriotomy followed by infusion of MgSO₄ (Mg-late group, n=16) from 10 minutes after removal of the vessel clamp. Thrombus area was significantly reduced by 75% in the Mg-early group (P<.005) but not in the Mg-late group compared with the control group. Mean number of emboli was reduced during magnesium infusion. The serum magnesium level increased to 2.2 (2.1 to 2.5) and 3.5 (3.0 to 4.2) mmol/L after infusion in the Mg-late and the Mg-early group, respectively. In the present study, intravenous infusion of MgSO₄ significantly reduced thrombus formation in vivo but only when it was given before reperfusion. The antithrombotic effect of magnesium may be utilized in patients with acute myocardial infarction to reduce the rate of reocclusion. Magnesium infusion may also be of value in elective arterial angioplasty, but this option has not been investigated in clinical trials. However, correct timing of magnesium administration is critical to obtain an efficient antithrombotic effect.

Key Words: magnesium • pharmacology • animal models • thrombosis drug therapy

This article has been cited by other articles:

				V. Rukshin, R. Santos, M. Gheorghiu, P. K. Shah, S. Kar, S. Padmanabhan, B. Azarbal, V. T. Tsang, R. Makkar, B. Samuels, et al. A Prospective, Nonrandomized, Open-Labeled Pilot Study Investigating the Use of Magnesium in Patients Undergoing Nonacute Percutaneous Coronary Intervention with Stent Implantation Journal of Cardiovascular Pharmacology and Therapeutics, September 1, 2003; 8(3): 193 - 200. [Abstract] [PDF]

				V. Rukshin, B. Azarbal, P. K. Shah, V. T. Tsang, M. Shechter, A. Finkelstein, B. Cercek, and S. Kaul Intravenous Magnesium in Experimental Stent Thrombosis in Swine Arterioscler Thromb Vasc Biol, September 1, 2001; 21(9): 1544 - 1549. [Abstract] [Full Text] [PDF]

				H. B. Ravn, U. Moeldrup, C. I. O. Brookes, L. B. Ilkjaer, P. White, M. Chew, L. Jensen, S. Johnsen, L. Birk-Soerensen, and V. E. Hjortdal Intravenous Magnesium Reduces Infarct Size After Ischemia/Reperfusion Injury Combined with a Thrombogenic Lesion in the Left Anterior Descending Artery Arterioscler Thromb Vasc Biol, March 1, 1999; 19(3): 569 - 574. [Abstract] [Full Text] [PDF]

				V. Rukshin, P. K. Shah, B. Cercek, A. Finkelstein, V. Tsang, and S. Kaul Comparative Antithrombotic Effects of Magnesium Sulfate and the Platelet Glycoprotein IIb/IIIa Inhibitors Tirofiban and Eptifibatide in a Canine Model of Stent Thrombosis Circulation, April 23, 2002; 105(16): 1970 - 1975. [Abstract] [Full Text] [PDF]